Search
Galapagos NV
GLPGAdd to Watchlist
27.730USD
0.0000.00%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.86BMarket Cap
4.32P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-05-07The current earnings forecast score of Galapagos NV is 4.67, ranking 345 out of 385 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 32.00 and a low of 22.00.
Analyst Rating
Based on
3
analysts
Sell
Current Rating
28.000
Target Price
-1.06%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Galapagos NV
GLPG
3
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Galapagos NV's expected revenue for the next quarter?
Galapagos NV's expected revenue is 9.11M.
What is Galapagos NV's price target?
Analysts forecast that Galapagos NV's price target is USD 28.00, with the highest forecast at USD 32.00 and the lowest forecast at USD 22.00.
How have Galapagos NVGLPG's recent earnings per share performed?
The market expectation was USD 0.25, while Galapagos NVGLPG's earnings per share (EPS) for the previous quarter was USD 13.94. EPS for the next quarter is expected at USD -5.30.
What is the analyst rating for Galapagos NV?
Based on the ratings of Galapagos NV's stock from 3 analysts, most analysts support a Sell trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Sell. Please note that this is not trading advice. You still need to conduct your own analysis.
